Treatment of patients with obese type 2 diabetes with tantalus-DIAMOND® gastric electrical stimulation: Normal triglycerides predict durable effects for at least 3 years

Hormone and Metabolic Research

Volumn 47, Issue 6, 2015, Pages 456-462

  Lebovitz, H E ^a   Ludvik, B ^b,c   Yaniv, I ^d   Schwartz, T ^e   Zelewski, M ^d   Gutterman, D D ^f  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Krankenanstalt Ruldolfstiftung   (Austria)

^d MetaCure (USA) Inc   (United States)

^e Biostatistics and Medical Device Research Division at GCP Clinical Studies   (Israel)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

body weight; diabetes mellitus type 2; HbA1c; hepatic glucose production; neuropeptides; obesity

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BRAIN; CROSS-SECTIONAL STUDY; DIAMOND DEVICE; DIASTOLIC BLOOD PRESSURE; DIGESTIVE THERAPEUTIC DEVICE; ELECTROSTIMULATION; FOLLOW UP; GASTRIC ELECTRICAL STIMULATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INTESTINE; LIVER; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT REDUCTION; BLOOD; DIABETES MELLITUS, TYPE 2; ELECTROSTIMULATION THERAPY; GLUCOSE BLOOD LEVEL; PROCEDURES; TREATMENT OUTCOME;

BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ELECTRIC STIMULATION THERAPY; HUMANS; OBESITY; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84930226036     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0035-1548944     Document Type: Article

References (38)

1. Bernard C. Lecons de Ohysiologie Experimentale Appliques a le Medecine. Paris J.-B. Balliere: 1854
2. Wang PY T., Caspi L., Lam CK L., Chari M., Li X., Light P. E., Gutierrez-Juarez R., Ang M., Schwartz G. J., Lam TK T. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature: 2008; 452 1012 1016
3. Breen D. M., Yue JT Y., Rasmussen B. A., Kokorovic A., Cheung GW C., Lam TK T. Duodenal PKC-δ and cholecystokinin signaling axis regulates glucose production. Diabetes: 2011; 60 3148 3153
4. Rasmussen B. A., Breen D. M., Luo P., Cheung GW C., Yang C. S., Sun B., Kokorvic A., Rong W., Lam TK T. Duodenal activation of cAMP-dependent protein kinase induces vagal afferent firing and lowers glucose production in rats. Gastroenterology: 2012; 142 834 843
5. Breen D. M., Rasmussen B. A., Cote C. D., Jackson M., Lam TK T. Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes. Diabetes: 2013; 62 3005 3012
6. Lam TK T. Neuronal regulation of homeostasis by nutrient sensing. Nat Med: 2010; 16 392 395
7. Schwartz M. W., Woods S. C., Porte D. Jr, Seeley R. J., Baskin D. G. Central nervous system control of food intake. Nature: 2000; 404 661 671
8. Schwartz M. W., Seeley R. J., Tschop M. H., Woods S. C., Morton G. J., Myers M. G., D'Alessio D. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature: 2013; 503 59 66
9. Policker S., Lu H., Haddad W., Aviv R., Kliger A., Glasberg O., Goode P. Electrical stimulation of the gut for the treatment of type 2 diabetes: the role of automatic eating detection. J Diabetes Sci Technol: 2008; 2 906 912
10. Peles S., Petersen J., Aviv R., Policker S., Abu-Hatoum O., Ben-Haim S. A., Gutterman D. D., Sengupta J. N. Enhancement of antral contraction and vagal afferent signaling with synchronized electrical stimulation. Am J Physiol Gastrointest Liver Physiol: 2003; 285 G577 G585
11. Lebovitz H. E., Ludvik B., Yaniv I., Haddad W., Schwartz T., Aviv R. Metacure Investigator Group Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm. Diabet Med: 2013; 30 687 693
12. ® system in obese type 2 diabetes patients: effect on weight and glycemic control. J Diab Sci Technol: 2009; 3 964 970
13. Bohdjalian A., Prager G., Rosak C., Weiner R., Jung R., Schramm M., Aviv R., Schindler K., Haddad W., Rosenthal N., Ludvik B. Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation. Obes Surg: 2009; 19 1221 1227
14. ® vs. supplementary insulin treatment in obese T2DM patients. Diabetes Technol Therap (in press 2015)
15. Primeaux S. D., Barnes M. J., Braymer H. D. Hypothalamic QRFP: regulation of foof intake and fat selection. Horm Metab Res: 2013; 45 967 974
16. Sekar R., Chow B. K. Role of secretin peptide family and their receptors in the hypothalamic control of energy homeostasis. Horm Metab Res: 2013; 45 945 954
17. Tonon M. C., Lanfray D., Castel H., Vaudry H., Morin F. Hypothalamic glucose-sensing: role of Glia-to-neuron signaling. Horm Metab Res: 2013; 45 955 959
18. Knauf C., Drougard A., Fournel A., Duparc T., Valet P. Hypothalamic actions of apelin on energy metabolism: new insights on glucose homeostasis and metabolic disorders. Horm Metab Res: 2013; 45 928 934
19. Kavalkova P., Touskova V., Roubicek T., Trachta P., Urbanova M., Drapalova J., Haluzikova D., Mraz M., Novak D., Matoulek M., Lacinova Z., Haluzik M. Serum preadipocyte factor-1 concentration in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment. Horm Metab Res: 2013; 45 820 826
20. Stirban A., Nandrean S., Gotting C., Stratmann B., Tschoepe D. Effects of n-3 polyunsaturated fatty acids (PUFAs) on circulating adiponectin and leptin in subjects with type 2 diabetes mellitus. Horm Metab Res: 2014; 46 490 492
21. Berthoud H. R., Patterson L. M. Anatomical relationship between vagal afferent fibers and CCK-immunoreactive entero-endocrine cells in the rat small intestinal mucosa. Acta Anat: 1996; 158 123 131
22. Timmermans J-P, Hens J., Adriaensen D. Outer submucous plexus: an intrinsic nerve network involved in both secretory and motility processes in the intestine of large mammals and humans. Anat Rec: 2001; 262 71 78
23. Cheung GW C., Kokorovic A., Lam CK L., Chari M., Lam TK T. Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab: 2009; 10 99 109
24. Cote C. D., Zadeh-Tahmasebi M., Rasmussen B. A., Duca F. A., Lam TK T. Hormonal signaling in the gut. J Biol Chem: 2014; 289 11642 11649
25. Lam TK T., Pocai A., Gutierrez-Juarez R., Obici S., Bryan J., Aguilar-Bryan L., Schwartz G. J., Rossetti L. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med: 2005; 11 320 327
26. TM system for obesity: effect on gastric emptying of solids and ghrelin plasma levels. Obes Surg: 2007; 17 1 6
27. Jones K. L., Horowitz M., Wishart J. M., Maddox A. F., Harding P. E., Chatterton B. E. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med: 1995; 36 2220 2228
28. Schvarcz E., Palmer M., Aman J., Horowitz M., Stridsberg M., Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology: 1997; 113 60 66
29. Woerle H-J, Albrecht M., Linke R., Zschau S., Neumann C., Nicolaus M., Gerich J., Goke B., Schirra J. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab: 2008; 294 E103 E109
30. Woerle H. J., Albreche M., Linke R., Zschau S., Neumann C., Nicolaus M., Gerich J. E., Goke B., Schirra J. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care: 2008; 31 2325 2331
31. Phillips L. K., Rayner C. K., Jones K. L., Horowitz M. Measurement of gastric emptying in diabetes. J Diab Complicat: 2014; 28 894 903
32. Kang Z. F., Deng Y., Zhou Y., Fan R. R., Chan JC N., Laybutt D. R., Luzuriaga J., Xu G. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signaling in the beta cell in mouse models of diabetes. Diabetologia: 2013; 56 423 433
33. Roth J. D., Erickson M. R., Chen S., Parkes D. G. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Brit J Pharmacol: 2011; 166 121 136
34. Van de Woestijne A. P., Monajemi H., Kalkhoven E., Visseren L. J. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev: 2011; 12 829 840
35. Graner M., Pentikainen M. O., Siren R., Nyman K., Lundbom J., Hakkarainen A., Lauerma K., Lundbom N., Nieminen M. S., Taskinen M. R. Electrocardiographic changes associated with insulin resistance. Nutr Metab Cardiovasc Dis: 2014; 24 315 320
36. Tiehuis A. M., van der Graaf Y., Mali W. P., Vincken K., Muller M., Geerlings M. I. SMART Study Group Metabolic syndrome, prediabetes, and brain abnormalities on MRI in patients with manifest arterial disease: the SMART-MR study. Diabetes Care: 2014; 37 2515 2521
37. Schilling S., Tzourio C., Dufouil C., Zhu Y., Berr C., Alperovitch A., Crivello F., Mazoyer B., Deberre S. Plasma lipids and cerebral small vessel disease. Neurology: 2014; 83 1844 1852
38. Lupi R., Dotta F., Marselli L., Del Guerra S., Masini M., Santangelo C., Patane G., Boggi U., Piro S., Anello M., Bergamini E., Mosca F., Di Mario U., Del Prato S., Marchetti P. Prolonged exposure to free fatty acids has cytostatic and proapoptotic effect on human pancreatic islets. Diabetes: 2002; 51 1437 1442